given intranasally to 81 patients before or 12 hours after inoculation with rhinovirus type 39 reduced total symptom scores by 45% and the proportion of patients with clinical colds by 23%, compared with 96 placebo patients, said Dr.
They have tried out one drug that does this, tremacamra
, in volunteers given cold viruses - and it reduced the severity of their subsequent colds.
The virus latches onto this decoy, called tremacamra, reducing the likelihood of infecting a cell.
Participants also collected their mucus-laden tissues in sealed containers, which revealed that untreated participants produced about twice as much mucus as those getting tremacamra did.
So it's great news that the drug Tremacamra
stops rhinoviruses attaching themselves to nose and throat surface cells.